HK1146386A1 - Pharmaceutical compositions containing at least one proteinaceous active ingredient protected against digestive enzymes - Google Patents

Pharmaceutical compositions containing at least one proteinaceous active ingredient protected against digestive enzymes

Info

Publication number
HK1146386A1
HK1146386A1 HK11100516.2A HK11100516A HK1146386A1 HK 1146386 A1 HK1146386 A1 HK 1146386A1 HK 11100516 A HK11100516 A HK 11100516A HK 1146386 A1 HK1146386 A1 HK 1146386A1
Authority
HK
Hong Kong
Prior art keywords
active ingredient
pharmaceutical compositions
compositions containing
digestive enzymes
protected against
Prior art date
Application number
HK11100516.2A
Other languages
English (en)
Inventor
Farid Bennis
Jean-Jacques Serrano
Original Assignee
Farid Bennis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Farid Bennis filed Critical Farid Bennis
Publication of HK1146386A1 publication Critical patent/HK1146386A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007—Effervescent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
HK11100516.2A 2007-12-19 2011-01-19 Pharmaceutical compositions containing at least one proteinaceous active ingredient protected against digestive enzymes HK1146386A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0759971A FR2925333B1 (fr) 2007-12-19 2007-12-19 Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives
PCT/FR2008/052357 WO2009083686A1 (fr) 2007-12-19 2008-12-18 Compositions pharmaceutiques renfermant au moins un principe actif proteinique protege des enzymes digestives

Publications (1)

Publication Number Publication Date
HK1146386A1 true HK1146386A1 (en) 2011-06-03

Family

ID=39671377

Family Applications (1)

Application Number Title Priority Date Filing Date
HK11100516.2A HK1146386A1 (en) 2007-12-19 2011-01-19 Pharmaceutical compositions containing at least one proteinaceous active ingredient protected against digestive enzymes

Country Status (19)

Country Link
US (1) US8309123B2 (xx)
EP (1) EP2234598A1 (xx)
JP (1) JP5676272B2 (xx)
KR (2) KR20150132887A (xx)
CN (1) CN101917967B (xx)
AP (1) AP3573A (xx)
AR (1) AR069847A1 (xx)
AU (1) AU2008345474B2 (xx)
BR (1) BRPI0821373B8 (xx)
CA (1) CA2709899C (xx)
EA (1) EA023107B1 (xx)
FR (1) FR2925333B1 (xx)
HK (1) HK1146386A1 (xx)
IL (1) IL206364A (xx)
MA (1) MA31927B1 (xx)
MX (1) MX2010006927A (xx)
TN (1) TN2010000290A1 (xx)
TW (1) TWI461226B (xx)
WO (1) WO2009083686A1 (xx)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120035103A1 (en) * 2010-01-29 2012-02-09 Pillion Dennis J Method for administration of insulin and pharmaceutical composition thereof
US9962336B2 (en) 2014-05-01 2018-05-08 Sun Pharmaceutical Industries Limited Extended release suspension compositions
US10258583B2 (en) 2014-05-01 2019-04-16 Sun Pharmaceutical Industries Limited Extended release liquid compositions of guanfacine
US20180104197A9 (en) 2014-05-01 2018-04-19 Sun Pharmaceutical Industries Limited Extended release liquid compositions of metformin
WO2016016845A1 (en) 2014-07-30 2016-02-04 Sun Pharmaceutical Industries Limited Dual-chamber pack
JP2017514903A (ja) 2014-05-01 2017-06-08 サン ファーマシューティカル インダストリーズ リミテッドＳｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｉｎｄｕｓｔｒｉｅｓ Ｌｔｄ． 徐放性懸濁組成物
AU2015341479B2 (en) 2014-11-04 2020-11-26 Innopharmax, Inc. Oral administration of unstable or poorly-absorbed drugs
US10238803B2 (en) 2016-05-02 2019-03-26 Sun Pharmaceutical Industries Limited Drug delivery device for pharmaceutical compositions
US10369078B2 (en) 2016-05-02 2019-08-06 Sun Pharmaceutical Industries Limited Dual-chamber pack for pharmaceutical compositions
FR3120189A1 (fr) * 2021-03-01 2022-09-02 Farid Bennis Composition pharmaceutique pour une administration par voie orale d’un agoniste du récepteur du GLP-1

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE36225B1 (en) 1971-01-28 1976-09-15 Nat Res Dev Improvements relating to insulin derivatives
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
EP0179904A1 (en) 1984-05-09 1986-05-07 Medaphore Inc. Oral insulin and a method of making the same
US4693433A (en) * 1986-06-06 1987-09-15 Merrill David Martin Unwind stand for web rolls
US6191105B1 (en) * 1993-05-10 2001-02-20 Protein Delivery, Inc. Hydrophilic and lipophilic balanced microemulsion formulations of free-form and/or conjugation-stabilized therapeutic agents such as insulin
GB9417524D0 (en) * 1994-08-31 1994-10-19 Cortecs Ltd Pharmaceutical compositions
EP0781142A4 (en) * 1994-09-01 2003-04-09 Allied Medical Res Associates COMPOSITIONS AND METHOD FOR PROVIDING POLYPEPTIDES
US5824638A (en) * 1995-05-22 1998-10-20 Shire Laboratories, Inc. Oral insulin delivery
US5912014A (en) * 1996-03-15 1999-06-15 Unigene Laboratories, Inc. Oral salmon calcitonin pharmaceutical products
US5783556A (en) * 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US6071539A (en) * 1996-09-20 2000-06-06 Ethypharm, Sa Effervescent granules and methods for their preparation
AU4894697A (en) * 1997-10-01 1999-04-23 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
SE9801495D0 (sv) * 1998-04-28 1998-04-28 Astra Ab Protein formulationa
US6531648B1 (en) * 1998-12-17 2003-03-11 Syngenta Participations Ag Grain processing method and transgenic plants useful therein
PT1031347E (pt) * 1999-01-27 2002-09-30 Idea Ag Transporte/imunizacao transnasal com veiculos muitissimo adaptaveis
SE9904121D0 (sv) * 1999-11-15 1999-11-15 Gustaf Jederstroem Hydrophobe biomolecular structure
US6531112B2 (en) * 2000-05-15 2003-03-11 Delrx Pharmaceutical Corporation Formulations for administering calcitonin and processes for preparing the same
US7060675B2 (en) * 2001-02-15 2006-06-13 Nobex Corporation Methods of treating diabetes mellitus
US7316819B2 (en) * 2001-03-08 2008-01-08 Unigene Laboratories, Inc. Oral peptide pharmaceutical dosage form and method of production
CN1335182A (zh) * 2001-08-08 2002-02-13 华中科技大学 胰岛素口腔喷剂及其制备工艺
GB0119859D0 (en) * 2001-08-15 2001-10-10 Qinetiq Ltd Eye tracking system
US20060258561A1 (en) * 2003-03-13 2006-11-16 Novo Nordisk A/S Novel NPH insulin preparations
KR100638041B1 (ko) * 2003-12-24 2006-10-23 주식회사 삼양사 수용성 약물의 경구투여용 나노입자 조성물 및 그의제조방법
EP1765406A4 (en) * 2004-05-21 2012-11-28 Mediplex Corp ADDITIVES FOR IMPROVED MUCOSAL ABSORPTION OF THERAPEUTIC AGENTS
PL1773878T3 (pl) * 2004-07-19 2015-07-31 Biocon Ltd Koniugaty insulina-oligomer, ich formulacje i zastosowania
EP1773376A4 (en) * 2004-08-03 2009-07-01 Emisphere Tech Inc ANTIDIBLE ORAL INSULIN BIGUANIDE COMBINATION
AU2006249480A1 (en) 2005-05-23 2006-11-30 Sdg, Inc. Lipid construct for delivery of insulin to a mammal
WO2007032018A1 (en) * 2005-09-15 2007-03-22 Council Of Scientific And Industrial Research pH SENSITIVE NANOPARTICLE FORMULATION FOR ORAL DELIVERY OF PROTEINS/PEPTIDES
WO2008048298A2 (en) * 2005-11-21 2008-04-24 Medivas, Llc Polymer particles for delivery of macromolecules and methods of use
WO2007121318A2 (en) * 2006-04-12 2007-10-25 Emisphere Technologies, Inc. Formulations for delivering insulin

Also Published As

Publication number Publication date
US8309123B2 (en) 2012-11-13
CN101917967A (zh) 2010-12-15
AR069847A1 (es) 2010-02-24
KR20100095449A (ko) 2010-08-30
WO2009083686A9 (fr) 2009-10-15
IL206364A0 (en) 2010-12-30
FR2925333B1 (fr) 2012-04-13
IL206364A (en) 2016-12-29
MX2010006927A (es) 2010-12-06
TN2010000290A1 (fr) 2011-11-11
BRPI0821373B8 (pt) 2021-05-25
MA31927B1 (fr) 2010-12-01
CA2709899C (fr) 2018-01-16
CA2709899A1 (fr) 2009-07-09
AU2008345474B2 (en) 2014-07-31
EP2234598A1 (fr) 2010-10-06
WO2009083686A1 (fr) 2009-07-09
CN101917967B (zh) 2013-05-22
JP5676272B2 (ja) 2015-02-25
BRPI0821373B1 (pt) 2020-04-22
AP3573A (en) 2016-02-08
EA201070746A1 (ru) 2011-02-28
AU2008345474A1 (en) 2009-07-09
AP2010005298A0 (en) 2010-06-30
TW200940107A (en) 2009-10-01
FR2925333A1 (fr) 2009-06-26
KR101592609B1 (ko) 2016-02-05
BRPI0821373A2 (pt) 2015-06-16
EA023107B1 (ru) 2016-04-29
US20090176691A1 (en) 2009-07-09
KR20150132887A (ko) 2015-11-26
TWI461226B (zh) 2014-11-21
JP2011506587A (ja) 2011-03-03

Similar Documents

Publication Publication Date Title
HK1146386A1 (en) Pharmaceutical compositions containing at least one proteinaceous active ingredient protected against digestive enzymes
WO2008036932A3 (en) Compositions and methods comprising boswellia species
WO2008016490A3 (en) Modified two-component gelation systems for the treatment of post-myocardial infarction
WO2008128775A3 (en) Stabilised pharmaceutical composition containing pregabaline
TR200801337T1 (tr) Suda zayıf çözülebilen farmasötik ajanlar ve antimikrobiyal ajanlar içeren kompozisyonlar.
UA91815C2 (ru) Выделенное антитело, которое специфически связывает gdf-8, и его применение
WO2007084221A9 (en) Methods and apparatus for identifying subject matter in view data
WO2007047207A3 (en) 5-lipoxygenase-activating protein (flap) inhibitors
WO2007056228A3 (en) 5-lipoxygenase-activating protein (flap) inhibitors
MX336769B (es) Particulados capaces de fluir.
WO2005117557A3 (en) Expression system
WO2008049042A3 (en) Ophthalmic compositions containing diglycine
WO2006040357A3 (en) Molecular targets and compounds, and methods to identify the same, useful in the treatment of joint degenerative and inflammatory diseases
MA30923B1 (fr) Composes et compositions inhibant la proteine kinase
WO2007079139A3 (en) Solid forms of n-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide
WO2009102367A3 (en) Tight junction protein modulators and uses thereof
WO2008068615A8 (en) Crystalline forms of ( 3 s ) -3- [n- (n' - (2-tert-butylphenyl) oxamyl) alaninyl] amino-5- (2 ', 3 ', 5 ', 6 ' -tetrafluoro phenoxy) -4-0x0penta noic acid
TW200716605A (en) 2,6-quinolinyl derivatives, processes for preparing them and their uses
WO2007025988A3 (en) Liquid formulations of pegylated growth hormone
WO2006118884A3 (en) Drug delivery devices and related components, systems and methods
TW200508197A (en) Indolone-acetamide derivatives, processes for preparing them and their uses
WO2007087026A3 (en) Solid-state form of amg 706 and pharmaceutical compositions thereof
WO2006008401A3 (fr) Composition comprenant un milieu de culture de microorganisme marin et/ou d'eau douce photosynthetique.
WO2007071444A3 (en) Esomeprazole arginine
WO2008063890A3 (en) Virus-mediated cytoplasmic expression of dna vaccines